According to Perrigo Company, which is partnered with Teva on a generic triamcinolone acetonide nasal spray, Teva has begun shipping the product. Perrigo developed the nasal spray, which is a generic equivalent of Sanofi’s Nasacort AQ, and is manufacturing it.
The US FDA approved the application for the product for the treatment of nasal symptoms resulting from allergies in adults and children aged 6 and older in August 2009. Barr Pharmaceuticals (now Teva) was the first to file an ANDA with Paragraph IV certification for Nasacort AQ, and Teva will have 180 days of generic exclusivity.
Perrigo Chairman and CEO Joseph Papa commented, “The launch of triamcinolone nasal spray is a terrific example of Perrigo’s strategic focus on developing challenging products in the extended topical categories. It further demonstrates our strategy to deliver quality affordable healthcare for generic prescriptions and over the counter products.”
Read the Perrigo press release.
